
    
      Jaktinib Dihydrochloride Monohydrate is a potent inhibitor of JAK1 and JAK2 that demonstrated
      efficacy and safty in preclinical study and safty in a phase 1 in healthy volunteerï¼›This
      phase IIB, open-label, multicenter study evaluated the efficacy and safety of oral Jaktinib
      Dihydrochloride in Intermediate-risk and High-risk Myelofibrosis and Previously Treated With
      Ruxolitinib
    
  